A Study of Mouth Rinses in Type 1 and Type 2 Diabetic Participants

NCT04449952 | Completed Phase 4

• 1 other identifier: CCSORC002281
• Study Type: interventional
• Target: 154
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate mouth rinse formulations for oral soft tissue tolerance and efficacy in plaque/ gingivitis prevention/reduction in Type 1 and Type 2 diabetics when used twice daily as an adjunct to tooth brushing during a twelve-week treatment period.

Conditions

Gingivits in Diabetics

Outcome Measures

Primary Outcomes (2)

• Whole-Mouth Mean Modified Gingival Index (MGI) Score After 12 Weeks of Product use

  Gingivitis will be assessed by the Modified Gingival Index on the buccal and lingual marginal gingivae and interdental papillae of all scorable teeth: 0 (Normal \[absence of inflammation\]), 1 (Mild inflammation \[slight change in color, little change in texture\] of any portion of the entire gingival unit); 2 (Mild inflammation of the entire gingival unit); 3 (Moderate inflammation \[moderate glazing, redness, edema, and/or hypertrophy\] of the gingival unit); 4 (Severe inflammation \[marked redness and edema/hypertrophy, spontaneous bleeding, or ulceration\] of the gingival unit).

  12 Weeks

• Whole Mouth Mean Turesky Plaque Index (TPI) Score After 12 Weeks of Product use

  Plaque area will be scored by the Turesky modification of the Quigley-Hein Plaque Index, on 6 surfaces (distobuccal, midbuccal and mesiobuccal, distolingual, midlingual and mesiolingual) of all scorable teeth, following disclosing: 0 (No Plaque); 1 (Separate flecks or discontinuous band of plaque around the gingival (cervical) margin); 2 (Thin (up to 1 millimeter \[mm\]), continuous band of plaque at the gingival margin); 3 (Band of plaque wider than 1mm but less than1/3 of the surface); 4 (Plaque covering 1/3 or more, but less than 2/3 of the surface); 5 (Plaque covering 2/3 or more of the surface).

  12 Weeks

Secondary Outcomes (4)

• Whole Mouth Mean Turesky Plaque Index (TPI) Score After 1 and 6 Weeks of Product use

  1 Week and 6 Weeks

• Whole-Mouth Mean Modified Gingival Index (MGI) Score After 6 Weeks of Product use

  6 Weeks

• Whole-Mouth Mean Expanded Bleeding Index (EBI) Score After 6 and 12 Weeks of Product use

  6 Weeks and 12 Weeks

• Percentage of Bleeding Sites, Based on the Expanded Gingival Bleeding Index Score After 6 and 12 Weeks of Product use

  6 Weeks and 12 Weeks

Study Arms (3)

AFEO-Containing Mouth Rinse

EXPERIMENTAL

Participants with Diabetes (Type 1 and 2) will be randomized to receive AFEO-containing mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 milliliter (mL) of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.

Other: Colgate Cavity Protection Toothpaste; Other: Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula; Device: Concept Curve Winter Series Toothbrush; Device: Listerine Cool Mint Floss

Listerine Cool Mint Mouth Rinse (Marketed product)

EXPERIMENTAL

Participants with Diabetes (Type 1 and 2) will be randomized to receive Listerine cool mint mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.

Other: Listerine Cool Mint; Other: Colgate Cavity Protection Toothpaste; Device: Concept Curve Winter Series Toothbrush; Device: Listerine Cool Mint Floss

5 Percent (%) Hydroalcohol Mouth Rinse

EXPERIMENTAL

Participants with Diabetes (Type 1 and 2) will be randomized to receive 5% Hydroalcohol mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.

Other: 5% Hydroalcohol Mouth Rinse; Other: Colgate Cavity Protection Toothpaste; Device: Concept Curve Winter Series Toothbrush; Device: Listerine Cool Mint Floss

Interventions

Listerine Cool Mint OTHER

Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing

Listerine Cool Mint Mouth Rinse (Marketed product)

5% Hydroalcohol Mouth Rinse OTHER

Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.

5 Percent (%) Hydroalcohol Mouth Rinse

Colgate Cavity Protection Toothpaste OTHER

Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.

5 Percent (%) Hydroalcohol Mouth Rinse; AFEO-Containing Mouth Rinse; Listerine Cool Mint Mouth Rinse (Marketed product)

Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula OTHER

Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.

AFEO-Containing Mouth Rinse

Concept Curve Winter Series Toothbrush DEVICE

Participants will brush teeth at least one minute with provided bristled toothbrush.

5 Percent (%) Hydroalcohol Mouth Rinse; AFEO-Containing Mouth Rinse; Listerine Cool Mint Mouth Rinse (Marketed product)

Listerine Cool Mint Floss DEVICE

Participants will use marketed fluoride-containing dentifrice, floss.

5 Percent (%) Hydroalcohol Mouth Rinse; AFEO-Containing Mouth Rinse; Listerine Cool Mint Mouth Rinse (Marketed product)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adequate oral hygiene (that is brush teeth daily and exhibit no signs of oral neglect)
• Able to comprehend and follow the requirements and restrictions of the study (including willingness to use the assigned study products per instructions, availability on scheduled visit dates and likeliness of completing the clinical study) based upon research site personnel's assessment
• Negative pregnancy urine tests (females of child bearing potential only)
• Females of childbearing potential must be using a medically-acceptable method of birth control for at least one month prior to Visit 1 and agree to continue using this method during their participation in the study
• A minimum of 20 gradable teeth including 4 molars with scorable both facial and lingual surfaces.Teeth that are grossly carious, extensively restored, orthodontically banded, abutments, exhibiting severe generalized cervical and/or enamel abrasion, teeth with veneers, or third molars will not be included in the tooth count
• Diabetes Type 1 or Type 2-self reported
• An HB A1C level less than (\<) 7.0 percent (%) for Type 1 Diabetes and an HB A1C level of \<8.0% for Type 2 Diabetes
• A mean gingival index greater than or equal to (\>=) 1.85 per the Modified Gingival Index at Baseline
• A mean plaque index \>= 1.95 per the 6 site Turesky modification of the Quigley-Hein Plaque Index at Baseline

You may not qualify if:

• Dental prophylaxis within four weeks prior to baseline visit
• More than 3 sites having pocket depths of 5 millimeter (mm) or any sites that are greater than 5 mm in depth
• History of medical conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures
• A recent history of hypoglycemia requiring medical intervention within the past 30 days
• Use of antibiotics, anti-inflammatory or anticoagulant therapy, phenytoin sodium or diphenylhydantoin, calcium channel blockers, cyclosporin A, immunostimulants/ immunomodulators during the study or within the one month prior to the Baseline exam. Intermittent use of certain anti-inflammatory medication is acceptable at the discretion of the investigator

Sponsors & Collaborators

• Johnson & Johnson Consumer Inc. (J&JCI): lead

Study Sites (1)

Salus Research, Inc.

Fort Wayne, Indiana, 46825, United States

Location

Related Publications (2)

• Leite RS, Marlow NM, Fernandes JK, Hermayer K. Oral health and type 2 diabetes. Am J Med Sci. 2013 Apr;345(4):271-273. doi: 10.1097/MAJ.0b013e31828bdedf.

  PMID: 23531957 BACKGROUND

• Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA; Clinical Guidelines Committee of the American College of Physicians; Fitterman N, Balzer K, Boyd C, Humphrey LL, Iorio A, Lin J, Maroto M, McLean R, Mustafa R, Tufte J. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018 Apr 17;168(8):569-576. doi: 10.7326/M17-0939. Epub 2018 Mar 6.

  PMID: 29507945 BACKGROUND

Related Links

• Related Info

MeSH Terms

Interventions

Ethanol

Intervention Hierarchy (Ancestors)

Alcohols; Organic Chemicals

Study Officials

• Jeffery Milleman

  Salus Research, Inc.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, CARE PROVIDER
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 24, 2020
• First Posted: June 29, 2020
• Study Start: December 2, 2019
• Primary Completion: March 6, 2020
• Study Completion: March 6, 2020
• Last Updated: August 7, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will share

Locations

US (1)